FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, wherein rings A, B and C are independently phenyl, pyridine and quinoline; R1 represents -(C3-C12)-heterocycloalkyl, -(C6-C20)-aryl, or -(C3-C20)-heteroaryl groups, optionally substituted by one or more substituents selected from - (C1-C12)-alkyl or -NH2; X, Y and Z are independently -O, -NH, or -N-(C1-C30)-alkyl; R2 represents =O; and R3 on ring A is -(C1-C30)-alkyl, -(C3-C12)-heterocycloalkyl, -(C6-C20)-aryl, -O-(C1-C12)-alkyl, -N-[(C1-C12)-alkyl]2, -COOH, -CN, -NH2 or halogen; R3 on ring C is hydrogen, -(C1-C30)-alkyl or halogen; provided that when R1 is unsubstituted pyridine or N-substituted –(C1)-alkyl pyridine, X, Y and Z are NH, R2 is =O, A is quinoline or pyridine, B is phenyl or pyridine, C is phenyl, R3 on ring C is hydrogen, then R3 on ring A is not -N-[(C1)-alkyl]2, -COOH, -CN and –F; when the compound has the structure of formula III
Formula III
R1 is unsubstituted pyridine, N-substituted -(C1-C3)-alkyl pyridine or pyrimidine substituted –(C1)-alkyl and NH2, X, Y, Z are -NH, R2 is =O, then R4 is not a halogen, -(C1)-alkyl, -O-(C1)-alkyl, -NH2 and -N-[(C1)-alkyl]2; when R1 is unsubstituted pyridine, unsubstituted quinoline or quinoline substituted with -NH2, -NO2, or -N-[(C1)-alkyl]2, X, Y, Z are -NH, R2 is =O, A is pyridine, B is phenyl, C is phenyl, R3 on ring C is hydrogen, then R3 on ring A is not –(C1-C2)-alkyl and -NH2; and when R1 is acridine, X, Y, Z are -NH, R2 is =O, A is pyridine, B is phenyl, C is phenyl, R3 on ring C is hydrogen, then R3 on ring A is not –(C1)-alkyl. The invention also relates to pharmaceutical compositions and methods for selective activation of Akt3.
Formula I
EFFECT: new compounds that can be used in medicine for the effective treatment of inflammatory, autoimmune diseases, graft-versus-host disease, chronic infection and obesity.
30 cl, 112 dwg, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USE THEREOF IN TREATING DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 OF IKAROS (IKZF2) FAMILY | 2019 |
|
RU2815714C2 |
| ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
| 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 (IKZF2) OF THE IKAROS FAMILY | 2019 |
|
RU2797559C2 |
| COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
| CALICHEAMICIN DERIVATIVES AND THEIR ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2732568C1 |
| AZALACTAM COMPOUNDS AS INHIBITORS OF HPK1 | 2021 |
|
RU2819642C1 |
| COMPOSITIONS AND METHODS RELATING TO DRUG CONJUGATES WITH ANTI-CD19 ANTIBODIES | 2019 |
|
RU2806333C2 |
| LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, ITS PRODUCTION METHOD AND ITS USE | 2019 |
|
RU2793316C2 |
| NEW NPR-B AGONISTS | 2010 |
|
RU2636738C2 |
| NEW PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF EYE DISEASE, CONTAINING PEPTIDE AS ACTIVE PHARMACEUTICAL INGREDIENT | 2018 |
|
RU2766160C2 |
